Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies
Clinical trial NCT04214418 · TERMINATED
Trial details
- NCT number
- NCT04214418
- Sponsor
- Columbia University
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-12
- Primary completion
- 2022-04-11
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.